Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patient type 2 with history of chronic heart failure(HFrEF) ,there is no prespecified inclusion criterion with respect to heart failure etiology and/or ejection fraction.~Exclusion Criteria:~1. Other etiologies of fluid overload different from heart failure.~2. Hyponatremia: Sodium level below 125mmol/l~3. Unstable patients: acute coronary syndrome, cardiogenic shock .~4. Patients requiring inotropic agents or renal dialysis.~5. Pregnancy or breastfeeding period.~6. sever hepatic disease~7. GFR is less than 45 mL/min/1.73 m² .~8. Patient with diabetic ketoacidosis or non ketotic hyperosmolar.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin group (Type: ACTIVE_COMPARATOR): 50 patients will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures.
- Placebo group (Type: PLACEBO_COMPARATOR): 50 patients will receive insulin for control of blood sugar plus diuretics and anti-failure measures.

Based on this trial design, predict the completion outcome and termination type (if applicable).